Q-omics provides the consensus-scored ABCB10P1 profile across patient tissues and cancer cell-line models. ABCB10P1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ABCB10P1 is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, ABCB10P1 RNA expression shows 7,656 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where ABCB10P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCB10P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCB10P1 survival associations across molecular data types. ABCB10P1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCB10P1 RNA expression–survival associations across cancer types. High ABCB10P1 expression shows unfavorable associations in THCA, BRCA and UCS, but favorable associations in KIRC, UCEC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ABCB10P1 RNA expression.
This table summarizes ABCB10P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ABCB10P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCB10P1 shows higher tumor expression in LIHC, LUSC and HNSC. The LIHC box plot shows higher ABCB10P1 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .004).
This table shows molecular features associated with ABCB10P1 in patient tissues and cancer cell lines. In patient samples, ABCB10P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
